PRECISE Scoring for Active Surveillance MRI
Active surveillance is commonly used for men with low-risk or selected favorable intermediate-risk prostate cancer. Instead of treating immediately, patients are followed with PSA testing, repeat biopsy when needed, and MRI. The challenge is that prostate MRI is not just about whether a lesion looks suspicious today. In active surveillance, the bigger question is: has anything changed?
That is where PRECISE scoring comes in.
PRECISE stands for Prostate Cancer Radiological Estimation of Change in Sequential Evaluation. It is a scoring system designed specifically for men with known prostate cancer who are being followed on active surveillance. Unlike PI-RADS, which estimates how suspicious a lesion looks on a single exam, PRECISE focuses on radiologic change between MRI scans.
Why PRECISE is different from PI-RADS
PI-RADS is used mainly for detecting and characterizing suspicious prostate lesions. It helps radiologists communicate how likely a lesion is to represent clinically significant prostate cancer.
PRECISE is different. It is used when a patient already has prostate cancer and is being monitored over time. The radiologist compares the current MRI with the patient’s prior MRI exams and decides whether the disease appears improved, stable, or worse.
A simple way to think about it:
| Score | Meaning | Plain-language interpretation |
|---|---|---|
| PRECISE 1 | Resolution | The prior suspicious finding is no longer visible |
| PRECISE 2 | Improvement | The finding is smaller or less conspicuous |
| PRECISE 3 | Stable | No meaningful change |
| PRECISE 4 | Progression | The lesion is larger, more conspicuous, or a new suspicious lesion appears |
| PRECISE 5 | Definite stage progression | Clear worsening such as extracapsular extension, seminal vesicle invasion, nodal disease, or metastatic disease |
PRECISE version 2 also separates stable disease into PRECISE 3-V, meaning stable but visible disease, and PRECISE 3-NonV, meaning stable nonvisible disease. This distinction matters because a stable visible lesion may not behave the same way as a patient with no visible lesion on MRI.
What radiologists look for
When assigning a PRECISE score, the radiologist compares the current MRI to both the baseline MRI and the most recent prior MRI. Important features include:
- Whether a known lesion has changed in size
- Whether the lesion has become more or less conspicuous
- Whether a new suspicious lesion has appeared
- Whether there is evidence of extracapsular extension or other stage progression
- Whether image quality is good enough to make a confident comparison
The updated PRECISE recommendations emphasize that MRI quality matters. If the study is not diagnostic enough to confidently assess change, the scan may be assigned PRECISE X rather than a 1–5 score.
What PRECISE progression means
A PRECISE score of 4 or 5 does not automatically mean a patient must leave active surveillance, but it does raise concern. In a large multicenter validation study, patients with PRECISE 4–5 had significantly higher odds of biopsy progression compared with patients whose MRI showed stability or regression.
That said, MRI is only one part of the decision. A PRECISE 4 lesion may lead to closer follow-up, targeted biopsy, or treatment discussion depending on the patient’s overall risk profile. PSA trend, PSA density, prior biopsy grade, lesion size, patient age, comorbidities, and patient preference all matter.
The bottom line
PRECISE scoring helps turn prostate MRI into a longitudinal monitoring tool. Instead of treating each MRI as an isolated snapshot, PRECISE asks whether the disease is improving, stable, or progressing.
For patients on active surveillance, that is often the most important question.
Related tools and articles
- PRECISE Assistant — generate a structured active surveillance assessment.
- PI-RADS v2.1 Quick Guide — review how PI-RADS differs from PRECISE.
- PSA Density in Prostate MRI — understand PSA density as a risk modifier.
References and further reading
- Englman C, Giganti F, Moore CM, et al. PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. European Urology. 2024.
- Updated Recommendations for Reporting Prostate MRI in Men on Active Surveillance: PRECISE 2. PubMed record.
- Giganti F, et al. Multicentre validation of the PRECISE scoring system for prostate MRI during active surveillance. European Radiology. 2026.
- Promoting the use of the PRECISE score for prostate MRI reporting during active surveillance. Insights into Imaging. 2022.